G. Stathopoulos (Athens, Greece), N. Rahman (Oxford, United Kingdom)
A requirement for kras signaling in malignant pleural effusion
A. Marazioti, A. Moustaki, M. Spella, A. Giannou, M. Iliopoulou, D. Kardamakis, G. Stathopoulos (Patras, Greece)
|  |
A myeloid NF-κbeta response in malignant pleural effusion
M. Spella, A. D. Giannou, A. Marazioti, D. Kardamakis, G. T. Stathopoulos (Patras, Greece)
| |
Recruitment and phenotypic characteristics of interleukin 9−Producing CD4+ T cells in malignant pleural effusion
X. Bu, Q. Zhou, J. C. Zhang, Z. J. Ye, Z. H. Tong, H. Z. Shi (Beijing, Wuhan, China)
|  |
The utility of survivin mRNA as a diagnostic biomarker in lung cancer with malignant pleural effusion
G. H. Abo El-Magd, A. S. Mohamed, O. Abd El-Fattah, A. Abd Elateef (Tanta, Egypt)
|  |
A conditional contribution of mast cells to malignant pleural effusion
A. D. Giannou, Z. Prijovic, A. Marazioti, M. Spella, C. Kairi, I. Giopanou, V. Papaleonidopoulos, D. Kardamakis, I. Kalomenidis, G. T. Stathopoulos (Patras, Athens, Greece)
| |
Elevated survivin is associated with a reduced survival in patients with malignant pleural effusion
D. Görgün, P. Yildiz, F. Secik, K. Midilli, V. Akkaya (Istanbul, Turkey)
| |
Impact of angiopoietin-1 in mesothelioma progression
S. Magkouta, C. Moschos, M. Spella, M. E. Vazakidou, I. Psallidas, A. Pappas, G. Stathopoulos, I. Kalomenidis (Athens, Patras, Greece)
| |